Eli Lilly and (LLY) Downgraded to Neutral at Goldman Sachs Group

Goldman Sachs Group cut shares of Eli Lilly and (NYSE:LLY) from a buy rating to a neutral rating in a research note published on Tuesday morning, MarketBeat.com reports. Goldman Sachs Group currently has $95.00 price target on the stock, up from their previous price target of $86.98.

Other equities analysts have also recently issued reports about the company. BMO Capital Markets set a $73.00 target price on Eli Lilly and and gave the stock a sell rating in a report on Tuesday, December 5th. Leerink Swann increased their target price on Eli Lilly and from $92.00 to $93.00 and gave the stock a market perform rating in a report on Monday, October 23rd. Credit Suisse Group reiterated a hold rating on shares of Eli Lilly and in a report on Wednesday, December 13th. Argus upgraded Eli Lilly and from a hold rating to a buy rating and increased their target price for the stock from $85.52 to $115.00 in a report on Friday, January 5th. Finally, Morgan Stanley set a $86.00 target price on Eli Lilly and and gave the stock a hold rating in a report on Friday, October 6th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the stock. The company presently has an average rating of Hold and an average price target of $92.75.

Shares of Eli Lilly and (NYSE:LLY) traded down $1.69 during mid-day trading on Tuesday, hitting $85.29. 4,878,300 shares of the stock traded hands, compared to its average volume of 2,955,040. The firm has a market cap of $94,930.00, a P/E ratio of 40.61, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. Eli Lilly and has a one year low of $74.00 and a one year high of $89.09. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66.

Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The company had revenue of $5.66 billion for the quarter, compared to analysts’ expectations of $5.52 billion. During the same period last year, the business earned $0.88 EPS. Eli Lilly and’s quarterly revenue was up 9.0% compared to the same quarter last year. equities analysts expect that Eli Lilly and will post 4.22 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be paid a dividend of $0.5625 per share. The ex-dividend date of this dividend is Wednesday, February 14th. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 annualized dividend and a yield of 2.64%. Eli Lilly and’s dividend payout ratio (DPR) is 99.05%.

In other news, major shareholder Lilly Endowment Inc sold 200,000 shares of the firm’s stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the completion of the sale, the insider now directly owns 123,084,104 shares of the company’s stock, valued at approximately $10,856,017,972.80. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Susan Mahony sold 36,585 shares of the firm’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $86.18, for a total value of $3,152,895.30. Following the sale, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at $4,729,989.30. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 251,088 shares of company stock worth $22,041,236. Company insiders own 0.20% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. Accredited Investors Inc. increased its position in shares of Eli Lilly and by 0.4% during the 2nd quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock valued at $268,000 after purchasing an additional 14 shares during the last quarter. Oakworth Capital Inc. increased its holdings in Eli Lilly and by 0.3% in the 2nd quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock worth $552,000 after acquiring an additional 20 shares during the last quarter. Sfmg LLC increased its holdings in Eli Lilly and by 0.5% in the 2nd quarter. Sfmg LLC now owns 4,258 shares of the company’s stock worth $350,000 after acquiring an additional 20 shares during the last quarter. Jackson Grant Investment Advisers Inc. increased its holdings in Eli Lilly and by 0.7% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,647 shares of the company’s stock worth $300,000 after acquiring an additional 24 shares during the last quarter. Finally, YorkBridge Wealth Partners LLC increased its holdings in Eli Lilly and by 0.8% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 3,199 shares of the company’s stock worth $265,000 after acquiring an additional 24 shares during the last quarter. 76.35% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Eli Lilly and (LLY) Downgraded to Neutral at Goldman Sachs Group” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://sportsperspectives.com/2018/01/17/eli-lilly-and-lly-downgraded-to-neutral-at-goldman-sachs-group.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply